ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Prostate Cancer

Biomarker Combo Could Predict Prostate Cancer Survival

A combination of biomarkers has shown promise as a surrogate for survival in clinical trials of metastatic castration-resistant prostate cancer. Image © Eugene Sim / Shutterstock.com.

Prostate Cancer

© decade3d - anatomy online/Shutterstock.com

Lethal prostate cancer is less—not more—likely to develop in patients with asthma. The Health Professionals Follow-up Study answers key questions about why.

Adding chemotherapy to hormonal therapy in men with metastatic hormone-sensitive prostate cancer increased improved overall survival by 13.6 months.

Researchers have identified a subset of six biomarkers that together may predict the risk of more aggressive prostate cancer among African American men.

In this interview we discuss recent trials that looked at the use of upfront chemotherapy combined with androgen deprivation therapy in men with metastatic prostate cancer and how they have changed clinical practice.

The 2015 ASCO Annual Meeting delivered new practice-changing results in the area of prostate cancer.

This article will describe the historic background of Ra-223; outline the clinical studies which led to phase III trials of this agent; highlight key results of these phase III studies; and explore possible future directions for use of Ra-223 and other alpha particles—both in prostate cancer and for management of other diseases.

Elucidation of the underlying mechanisms of action for Ra-223 will soon expand its clinical utility with respect to improved patient selection and integrated bone-targeted therapies.

Pages

Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.